AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...
Explore how integrated scenario modeling helps pharma leaders navigate pricing uncertainty and the complexity of global ...
The parent of cell therapy maker Gamida Cell will be the lead bidder in a court-supervised auction of Karyopharm, which ...
The 130% premium in Merck KGaA’s buyout of Silence Therapeutics is the second-highest paid in a biopharmaceutical company purchase this year, according to BioPharma Dive data. The notice adds to ...
At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share ...
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood ...
The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or ...
The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher ...
The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become ...
The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro ...
RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested ...
Etiome, Cellarity and Empress Therapeutics are being combined into one new AI-aided drugmaker claiming to possess the ability ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results